Piper Jaffray analyst Matt O'Brien recommends using the selloff today in shares of Boston Scientific after the FDA ordered all manufacturers of surgical mesh intended for transvaginal repair to stop selling and distributing their products immediately as a buying opportunity. Mesh products have been declining for several years at Boston Scientific and represented only ~1% of revenue in 2018, O'Brien tells investors in an intraday research note. The analyst estimates the company's revenue will be negatively impacted by less than $50M in 2019. Further, Boston Scientific is currently working with the FDA on a resolution, adds the analyst. Boston Scientific still has a "plethora of high-growth product launches fully intact" including Lotus, Acurate neo, and Watchman in Japan, "which should help cushion any lost revenue," says O'Brien. He has an Overweight rating on the shares with a $42 price target. The stock in afternoon trading is down 4% to $36.34.

RBC Capital raised the firm's price target on Boston Scientific to $82 from $78 and keeps an Outperform rating on the shares. Given the company's Q1 momentum on seales and earnings, along with its new product ramp, the management's updated FY24 guidance is likely "conservative" despite easier comps, the analyst tells investors in a research note. RBC adds that the stock is its top pick in the Sector based on its "industry-leading growth profile".

Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."

Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.

Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here